Brilacidin
Brilacidin
Also known as: PMX-30063, Defensin Mimetic, Host Defense Peptide Mimetic
Overview
Key Facts
Primary Goal: Research and therapeutic applications of Brilacidin
Mimics the amphipathic structure of human beta-defensins. Disrupts bacterial membrane integrity via electrostatic interaction.
Dosing Information
~8 hours
0.6–1.2 mg
1x daily
7-14 days (acute infection), longer for chronic use
Benefits
- Broad-spectrum antimicrobial activity (Gram-positive and Gram-negative bacteria)
- Anti-biofilm activity against drug-resistant organisms
- Immunomodulatory effects that enhance host defence
- Low propensity for bacterial resistance development
- Anti-inflammatory properties complementing antimicrobial action
- Potential antiviral activity against enveloped viruses
Side Effects
Mechanism of Action
Mimics the amphipathic structure of human beta-defensins
Disrupts bacterial membrane integrity via electrostatic interaction
Inhibits bacterial lipopolysaccharide (LPS) signaling
Modulates macrophage and dendritic cell cytokine profiles
Resists common bacterial resistance mechanisms (efflux pumps, enzymatic degradation)
Contraindications
Do not use this peptide if any of the following apply:
- Known hypersensitivity to defensin-mimetic compounds
- Severe hepatic impairment
- Pregnancy or breastfeeding
- Concurrent nephrotoxic agent use (monitor renal function)
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
Developed by Innovation Pharmaceuticals (formerly Cellceutix). Completed Phase 2 clinical trials for acute bacterial skin and skin structure infections (ABSSSI) with positive results. Also studied for oral mucositis and inflammatory bowel disease. Investigated as potential COVID-19 therapeutic. Represents a novel class of non-peptide immune defence mimetics.
Frequently Asked Questions
Common questions about Brilacidin
UK-Specific Information
Exclusive data points and guidance for UK residents using Brilacidin
UK Lab Testing
UK Lab Testing
Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.
Share on TikTok
Generate a trackable link to share this peptide information on TikTok